Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Corcept Therapeutics Incorporated (CORT : NSDQ)

• Company Description    Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone), is approved for the once-daily oral treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, suffering from type II diabetes or glucose intolerance and who have failed surgery or are not suitable for surgery. Number of Employees: 500

• Price / Volume Information    Yesterday's Closing Price: $72.01 Daily Weekly Monthly 20 Day Moving Average: 1,487,192 shares Shares Outstanding: 106.04 (millions) Market Capitalization: $7,636.28 (millions) Beta: 0.15 52 Week High: $117.33 52 Week Low: $31.18 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.17% -2.62% 12 Week 15.70% -2.68% Year To Date 42.90% 33.83%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 101 REDWOOD SHORES PARKWAY - REDWOOD CITY,CA 94065 USA ph: 650-688-8803 fax: 650-327-3218 ir@corcept.com http://www.corcept.com

• General Corporate Information    Officers Joseph K. Belanoff - Chief Executive Officer; Presiden James N. Wilson - Chairman of the Board of Directors Atabak Mokari - Chief Financial Officer Joseph Douglas Lyon - Chief Accounting and Technology Officer Gillian Cannon - Director Peer Information Corcept Therapeutics Incorporated (GSAC) Corcept Therapeutics Incorporated (CASI) Corcept Therapeutics Incorporated (ALCD.) Corcept Therapeutics Incorporated (OMNN) Corcept Therapeutics Incorporated (CGPI.) Corcept Therapeutics Incorporated (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 218352102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/04/25 Share - Related Items Shares Outstanding: 106.04 Most Recent Split Date: (:1) Beta: 0.15 Market Capitalization: $7,636.28 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.38 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $1.39 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/25

• Fundamental Ratios P/E Current FY Estimate: 51.71 Trailing 12 Months: 62.08 PEG Ratio: - Price Ratios Price/Book: 11.18 Price/Cash Flow: 57.98 Price / Sales: 11.14 EPS Growth vs. Year Ago Period: -32.00% vs. Previous Quarter: -34.62% Sales Growth vs. Year Ago Period: 7.09% vs. Previous Quarter: -13.57% ROE 06/30/25 - - 03/31/25 - 20.40 12/31/24 - 22.69 ROA 06/30/25 - - 03/31/25 - 16.64 12/31/24 - 18.66 Current Ratio 06/30/25 - - 03/31/25 - 3.07 12/31/24 - 3.35 Quick Ratio 06/30/25 - - 03/31/25 - 2.96 12/31/24 - 3.26 Operating Margin 06/30/25 - - 03/31/25 - 19.33 12/31/24 - 20.70 Net Margin 06/30/25 - - 03/31/25 - 19.33 12/31/24 - 20.70 Pre-Tax Margin 06/30/25 - - 03/31/25 - 19.86 12/31/24 - 23.92 Book Value 06/30/25 - - 03/31/25 - 6.44 12/31/24 - 6.49 Inventory Turnover 06/30/25 - - 03/31/25 - 1.00 12/31/24 - 1.21 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©